CN103638262B - 妇科止血灵胶囊 - Google Patents
妇科止血灵胶囊 Download PDFInfo
- Publication number
- CN103638262B CN103638262B CN201310710318.4A CN201310710318A CN103638262B CN 103638262 B CN103638262 B CN 103638262B CN 201310710318 A CN201310710318 A CN 201310710318A CN 103638262 B CN103638262 B CN 103638262B
- Authority
- CN
- China
- Prior art keywords
- radix
- herba
- capsule
- blood
- zhixueling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 241001057584 Myrrha Species 0.000 claims description 3
- 241000195474 Sargassum Species 0.000 claims description 3
- 239000009286 sanguis draxonis Substances 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 24
- 230000007812 deficiency Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 14
- 206010027514 Metrorrhagia Diseases 0.000 description 11
- 235000009161 Espostoa lanata Nutrition 0.000 description 9
- 240000001624 Espostoa lanata Species 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 231100000319 bleeding Toxicity 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 5
- 230000003821 menstrual periods Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 210000004914 menses Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002513 anti-ovulatory effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 229940035811 conjugated estrogen Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000008217 follicular development Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011121 vaginal smear Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001133184 Colletotrichum agaves Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 剂量(g/Kg) | 动物数量 | 子宫出血量(ml) |
模型组 | 20 | 0.532±0.237 | |
对照组(宫血宁胶囊) | 0.1 | 20 | 0.145±0.153 |
实施例1组 | 0.1 | 20 | 0.099±0.169 |
实施例2组 | 0.1 | 20 | 0.042±0.077 |
组别 | 治愈 | 好转 | 未愈 | 总有效率 |
对照组 | 19 | 24 | 8 | 84.3% |
实施例1组 | 22 | 26 | 3 | 94.1% |
实施例2组 | 29 | 22 | 0 | 100% |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310710318.4A CN103638262B (zh) | 2013-12-22 | 2013-12-22 | 妇科止血灵胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310710318.4A CN103638262B (zh) | 2013-12-22 | 2013-12-22 | 妇科止血灵胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103638262A CN103638262A (zh) | 2014-03-19 |
CN103638262B true CN103638262B (zh) | 2015-09-23 |
Family
ID=50243634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310710318.4A Active CN103638262B (zh) | 2013-12-22 | 2013-12-22 | 妇科止血灵胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103638262B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105031571A (zh) * | 2015-06-30 | 2015-11-11 | 孙霞 | 一种治疗子宫出血的中药 |
CN105497419A (zh) * | 2015-12-24 | 2016-04-20 | 韩志强 | 一种妇科止血灵及其制备方法 |
CN105560735A (zh) * | 2016-01-30 | 2016-05-11 | 王月水 | 一种治疗功能失调性子宫出血的组合物及其制备方法 |
CN107951994A (zh) * | 2017-12-18 | 2018-04-24 | 李丽 | 一种妇科止血灵胶囊 |
CN111973698A (zh) * | 2020-08-27 | 2020-11-24 | 翔宇药业股份有限公司 | 妇科止血灵胶囊的制备工艺 |
-
2013
- 2013-12-22 CN CN201310710318.4A patent/CN103638262B/zh active Active
Non-Patent Citations (3)
Title |
---|
HPLC法测定妇科止血灵胶囊中芍药苷的含量;卫昊等;《河南中医》;20110831;第31卷(第8期);939-940 * |
妇科止血灵治疗功血300例临床观察报告;李桂民等;《吉林中医药》;19861231(第3期);11 * |
姜新等,.妇科止血灵片在药流后阴道出血中的应用及护理方法.《按摩与康复医学》.2010,第1卷(第7期),77. * |
Also Published As
Publication number | Publication date |
---|---|
CN103638262A (zh) | 2014-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103638262B (zh) | 妇科止血灵胶囊 | |
CN102258685B (zh) | 治疗卵巢储备功能下降的复方中药及应用 | |
CN103520698A (zh) | 一种治疗痛经的药物 | |
CN103156981B (zh) | 治疗子宫发育不良的中药组合物及其制备方法和应用 | |
CN100506247C (zh) | 一种内服治疗功能性子宫出血的中药组合物 | |
CN103349766A (zh) | 一种用于产后恶露不尽的药物组合物 | |
CN105213472A (zh) | 一种包含断血流的止血口服液 | |
CN103479887B (zh) | 一种治疗更年期功血的中药组方 | |
CN101664525B (zh) | 一种治疗妇科疾病的中药及其制备方法 | |
CN103263650B (zh) | 一种调理女性月经的中药 | |
CN103071018B (zh) | 治疗早期习惯性流产的中药制剂 | |
CN103611110B (zh) | 一种用于治疗功能性子宫出血的中药组合物 | |
CN103479859B (zh) | 一种治疗多囊卵巢综合征高雄激素血症的中药组合物 | |
CN105797046A (zh) | 一种用于子宫肌瘤治疗与术后护理的中药组合物 | |
CN105943758B (zh) | 一种治疗不孕症的中药组合物及其应用 | |
CN101757309B (zh) | 一种治疗崩漏的药物及其制备工艺 | |
CN102247505A (zh) | 一种治疗经产母牛屡配不孕症的中药组合物及治疗方法 | |
CN103566310B (zh) | 一种用于月经不调的中药药物 | |
CN103611027B (zh) | 一种临床预防、护理和治疗滴虫性阴道炎的药物组合物 | |
CN105031418A (zh) | 一种治疗特发性高泌乳素血症的中药组合物 | |
CN101698037B (zh) | 一种治疗崩漏的药物及其制备工艺 | |
CN104436121A (zh) | 一种治疗月经不调、小腹胀满、久不受孕的药物 | |
CN104173981A (zh) | 一种治疗子宫肌瘤及子宫肥大症的汤剂药物及制备方法 | |
CN105194511A (zh) | 用于功能性子宫出血和产后出血的药物组合物 | |
CN102552815B (zh) | 一种治疗子宫内膜异位症性不孕症的中药汤剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIN FANYOU Effective date: 20140710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140710 Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Applicant after: Shandong Xiangyu Health Pharmaceutical Co., Ltd. Address before: 276023 Beijing road Shandong Linyi Province, Linyi City Economic Development Zone No. 30 Shandong Xiangyu Health Pharmaceutical Co. Ltd. Applicant before: Lin Fanyou |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Applicant after: Xiang Yu Pharmaceutical limited company Address before: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Applicant before: Shandong Xiangyu Health Pharmaceutical Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. TO: XIANGYU PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Fuke zhizhiling capsule Effective date of registration: 20220224 Granted publication date: 20150923 Pledgee: Linshang Bank Co.,Ltd. jinqueshan sub branch Pledgor: XIANGYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980001870 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |